Infographic: Cancer Deal-Making In 2020

Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 23 with upfront value of at least $100m.

Cancer Deals of 2020

2020 has been a hectic deal-making year for the biopharmaceutical industry, with the most significant deals – Gilead Sciences, Inc./Immunomedics, Inc. and Merck & Co., Inc./Seattle Genetics, Inc. – occurring in recent days, despite the ongoing COVID-19 pandemic. Deal-making in cancer has been particularly voluminous, continuing the trend of recent years. In this infographic, we mine information from Scrip coverage from the and the Biomedtracker database to provide a snapshot of the year’s cancer deal-making as of mid-September – highlighting the most significant acquisitions and alliances, gathering in one place the highest-value transactions, and also depicting which companies were most active and what development stages and therapeutic modalities saw the greatest activity.

To download this infographic, click here.

More from Deals

More from Business